0.00Open4.50Pre Close0 Volume0 Open Interest250.00Strike Price0.00Turnover0.00%IV0.31%PremiumDec 20, 2024Expiry Date3.73Intrinsic Value100Multiplier-28DDays to Expiry0.77Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma54.73Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet